Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
- Author
- MILES, David1 ; BASELGA, José2 ; AMADORI, Dino3 ; SUNPAWERAVONG, Patrapim4 ; SEMIGLAZOV, Vladimir5 ; KNOTT, Adam6 ; CLARK, Emma6 ; ROSS, Graham6 ; SWAIN, Sandra M7
[1] Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, United Kingdom
[2] Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, United States
[3] IRCCS Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST), Meldola, Italy
[4] Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand
[5] NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation
[6] Roche Products Limited, Welwyn Garden City, United Kingdom
[7] Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, United States - Source
Breast cancer research and treatment. 2013, Vol 142, Num 1, pp 89-99, 11 p ; ref : 29 ref
- CODEN
- BCTRD6
- ISSN
- 0167-6806
- Scientific domain
- Medical oncology; Obstetrics, gynecology, andrology; Pharmacology drugs
- Publisher
- Springer, Dordrecht
- Publication country
- Netherlands
- Document type
- Article
- Language
- Russian
- Author keyword
- Elderly HER2 Metastatic breast cancer Older women Pertuzumab Trastuzumab
- Keyword (fr)
- Anticancéreux Cancer du sein Chimiothérapie Docétaxel Essai clinique phase III Etude double insu Femelle Gène erbB2 Gène onc cellulaire Métastase Personne âgée Pertuzumab Placebo Protooncogène Randomisation Sous groupe Stade avancé Traitement Trastuzumab Anti-HER2 Récepteur HER2 Anticorps monoclonal Antimitotique Cancer Dérivé du taxane Homme Pathologie de la glande mammaire Pathologie du sein Tumeur maligne
- Keyword (en)
- Antineoplastic agent Breast cancer Chemotherapy Docetaxel Phase III trial Double blind study Female erbB2 Gene C-Onc gene Metastasis Elderly Pertuzumab Placebo Protooncogene Randomization Subgroup Advanced stage Treatment Trastuzumab Human Epidermal growth factor Receptor 2 Monoclonal antibody Antimitotic Cancer Taxane derivatives Human Mammary gland diseases Breast disease Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pecho Quimioterapia Docetaxel Ensayo clínico fase III Estudio doble ciego Hembra Gen erbB2 Gen onc celular Metástasis Anciano Pertuzumab Placebo Protooncogen Aleatorización Subgrupo Estadio avanzado Tratamiento Trastuzumab Anticuerpo monoclonal Antimitótico Cáncer Taxane derivado Hombre Glándula mamaria patología Seno patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27948114
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s10549-013-2710-z 
https://dx.doi.org/10.1007/s10549-013-2710-z
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-013-2710-z\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"142\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"89\";s:8:\"\u0000*\u0000epage\";s:2:\"99\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"MILES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"BASELGA, Jos\u00e9\";i:1;s:13:\"AMADORI, Dino\";i:2;s:23:\"SUNPAWERAVONG, Patrapim\";i:3;s:20:\"SEMIGLAZOV, Vladimir\";i:4;s:11:\"KNOTT, Adam\";i:5;s:11:\"CLARK, Emma\";i:6;s:12:\"ROSS, Graham\";i:7;s:15:\"SWAIN, Sandra M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-013-2710-z\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"142\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"89\";s:8:\"\u0000*\u0000epage\";s:2:\"99\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"MILES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"BASELGA, Jos\u00e9\";i:1;s:13:\"AMADORI, Dino\";i:2;s:23:\"SUNPAWERAVONG, Patrapim\";i:3;s:20:\"SEMIGLAZOV, Vladimir\";i:4;s:11:\"KNOTT, Adam\";i:5;s:11:\"CLARK, Emma\";i:6;s:12:\"ROSS, Graham\";i:7;s:15:\"SWAIN, Sandra M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-013-2710-z\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-013-2710-z\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"142\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"89\";s:8:\"\u0000*\u0000epage\";s:2:\"99\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"MILES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"BASELGA, Jos\u00e9\";i:1;s:13:\"AMADORI, Dino\";i:2;s:23:\"SUNPAWERAVONG, Patrapim\";i:3;s:20:\"SEMIGLAZOV, Vladimir\";i:4;s:11:\"KNOTT, Adam\";i:5;s:11:\"CLARK, Emma\";i:6;s:12:\"ROSS, Graham\";i:7;s:15:\"SWAIN, Sandra M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-013-2710-z\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"142\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"89\";s:8:\"\u0000*\u0000epage\";s:2:\"99\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"MILES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"BASELGA, Jos\u00e9\";i:1;s:13:\"AMADORI, Dino\";i:2;s:23:\"SUNPAWERAVONG, Patrapim\";i:3;s:20:\"SEMIGLAZOV, Vladimir\";i:4;s:11:\"KNOTT, Adam\";i:5;s:11:\"CLARK, Emma\";i:6;s:12:\"ROSS, Graham\";i:7;s:15:\"SWAIN, Sandra M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10549-013-2710-z\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Breast cancer research and treatment\";s:9:\"\u0000*\u0000stitle\";s:24:\"Breast cancer res. treat\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"142\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"89\";s:8:\"\u0000*\u0000epage\";s:2:\"99\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6806\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"MILES\";s:10:\"\u0000*\u0000aufirst\";s:5:\"David\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"BASELGA, Jos\u00e9\";i:1;s:13:\"AMADORI, Dino\";i:2;s:23:\"SUNPAWERAVONG, Patrapim\";i:3;s:20:\"SEMIGLAZOV, Vladimir\";i:4;s:11:\"KNOTT, Adam\";i:5;s:11:\"CLARK, Emma\";i:6;s:12:\"ROSS, Graham\";i:7;s:15:\"SWAIN, Sandra M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCTRD6\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)\";s:8:\"\u0000*\u0000place\";s:9:\"Dordrecht\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
